ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "autoimmune diseases"

  • Abstract Number: 1471 • ACR Convergence 2020

    Healthy Lifestyle and Risk of Rheumatoid Arthritis in Women: A Prospective Cohort Study

    Jill Hahn1, May Choi2, Susan Malspeis3, Emma Stevens4, Elizabeth Karlson4, Kazuki Yoshida5, Laura Kubzansky6, Jeffrey Sparks7 and Karen Costenbader8, 1Brigham and Womens' Hospital, Newton, MA, 2Brigham and Women's Hospital | Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, 3Brigham and Women's Hospital, Boston, 4Brigham and Women's Hospital, Boston, MA, 5Brigham & Women's Hospital and Harvard Medical School, Boston, MA, 6Harvard T.H. Chan School of Public Health, Boston, MA, 7Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, 8Brigham and Women's Hospital and Harvard Medical School, Boston, MA

    Background/Purpose: Many potentially modifiable biobehavioral factors have been associated with the risk of developing rheumatoid arthritis (RA), but the benefit of adopting an overall healthy…
  • Abstract Number: 1750 • ACR Convergence 2020

    Longitudinal Change in the Central Nervous System Pain Response After Treatment with Certolizumab or Placebo. a Post-hoc Analysis from the Pre-CEPRA Trial

    Juergen Rech1, Hannah Schenker2, Koray Tascilar1, Melanie Hagen2, Larissa Valor Mendez2, Verena Schoenau3, Marina Sergeeva4, Jutta Prade4, Mageshvar Sulvakumar5, Laura Konert6, Arnd Kleyer1, David Simon1, Sandra Strobelt4, Frank Behrens7, Christoph Baerwald8, Stephanie Finzel9, Reinhard Voll10, Axel Hueber11, Eugen Feist12, Julie Roesch13, José A. P. da Silva14, Arnd Doerfler13, Nemanja Damjanov15, Andreas Hess16 and Georg Schett17, 1Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Bayern, Germany, 2Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054, Erlangen, Germany, Erlangen, Germany, 3Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054, Erlangen, Germany, Erlangen, 4Institute for Experimental Pharmacology, Erlangen, Germany, 5Insitute for Experimental Pharmacology, FAU Erlangen-Nuremberg, Erlangen, Germany, 6Institute for Experimental Pharmacology, FAU Erlangen-Nürnberg, Erlangen, 7CIRI/Rheumatology & Fraunhofer TMP, Goethe University, Frankfurt, Germany, 8Uniklinik Leipzig, Medizinische Klinik III - Bereich Rheumatologie, Leipzig, Germany, 9Universitätsklinikum Freiburg, Klinik für Rheumatologie und Klinische Immunologie, Freiburg, Germany, 10Universitätsklinikum Freiburg, Klinik für Rheumatologie und Klinische Immunologie, Freibrug, 11Section Rheumatology, Sozialstiftung Bamberg, Bamberg, Germany, 12Department of Rheumatology, Helios Vogelsang-Gommern, Vogelsang-Gommern, Germany, 13Abteilung für Neuroradiologie, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054, Erlangen, Germany, Erlangen, Germany, 149.Centro Hospitalar e Universitário Coimbra (Rheumatology Department), Coimbra, Portugal, Coimbra, Portugal, 15Belgrade University School of Medicine, Belgrade, Serbia, 16Institute for Experimental Pharmacology, Erlangen, 17Friedrich-Alexander-Universität Erlangen- Nuremberg, Erlangen, Germany

    Background/Purpose: Biologicals - bring a hope of recovery or amelioration to people suffering from RA, but only half of the patients respond to such treatment.…
  • Abstract Number: PP05 • ACR Convergence 2020

    Coping Through Advocacy – My Story Living with Relapsing Polychondritis

    Allegonda Imeson1, 1The Canadian Society for Relapsing Polychondritis, Stony Plain, AB, Canada

    Background/Purpose: Becoming a mother was the most pivotal moment of my life. From early on, I instilled the importance of a physical, healthy lifestyle for my two…
  • Abstract Number: 0037 • ACR Convergence 2020

    Lipoprotein-associated Phospholipase A2: A New Biomarker for Lymphoma Development in Sjögren’s Syndrome

    Adrianos Nezos1, Eleni Kotsifaki1, Charalampos Skarlis2, Konstantinos Markakis1, Haralampos Moutsopoulos3, Michael Koutsilieris1, Clio Mavragani1 and Anna Psarrou1, 1National & Kapodistrian University of Athens, Athens, Greece, 2National &Kapodistrian University of Athens, Athens, Greece, 3National & Kapodistrian University of Athens/ Academy of Athens, Athens, Greece

    Background/Purpose: B-cell non-Hodgkin's lymphoma (B-NHL) is one of the major complications of primary Sjögren’s syndrome (SS). Chronic inflammation and macrophages in SS minor salivary glands…
  • Abstract Number: 0417 • ACR Convergence 2020

    Different Immunophenotypes Characterized IgG4-Related Disease Clinical Phenotypes

    Eduardo Martin-Nares1, Janette Furuzawa-Carballeda1, Ángel Alexis Priego-Ranero1, Isela Chan-Campos1, Gladys Sulikey Herrera-Noguera1, Fidel López-Verdugo1 and Gabriela Hernandez-Molina1, 1Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Distrito Federal, Mexico

    Background/Purpose: Patients with IgG4-related disease (IgG4-RD) can be classified in clinical phenotypes which differ in terms of demographics, clinical and serological features. Whether there are…
  • Abstract Number: 0606 • ACR Convergence 2020

    A Systematic Review Exploring Pre-COVID-19 Telehealthcare Models Used in the Management of Patients with Rheumatological Disease

    Alexandra Nelson1 and Marina Anderson2, 1University of Liverpool, Liverpool, United Kingdom, 2Lancaster University, Lancaster, United Kingdom

    Background/Purpose: Recent advancements in the delivery and utilization of information and communication technologies (ICTs) have led to an increased application of telehealthcare services. Global coronavirus…
  • Abstract Number: 0866 • ACR Convergence 2020

    Identifying an SLE Patient Cluster with Greater Treatment Effect: Immune Cell Deconvolution of Gene Expression in Two Atacicept Phase II Studies

    Joan Merrill1, Matthew Studham2, Eric Morand3, Aida Aydemir2, Cristina Vazquez Mateo2, Alex Rolfe2, Amy Kao2 and Robert Townsend2, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2EMD Serono (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, 3Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia

    Background/Purpose: Atacicept, a dual inhibitor of the B lymphocyte stimulator and a proliferation-inducing ligand (APRIL), has been associated with a reduction of flares in the…
  • Abstract Number: 1054 • ACR Convergence 2020

    Treatment with Certolizumab Pegol in Refractory Uveitis Secondary to Inmune-Mediated Inflammatory Diseases. Multicenter Study of 39 Patients

    José Luis Martín-Varillas1, Vanesa Calvo-Río2, Lara Sanchez-Bilbao2, Inigo Gonzalez-Mazon3, Ignacio Torre4, Alvaro García Martos5, Amalia Sánchez Andrade6, Angel García Aparicio7, Juan Ramón De dios8, Ana Urriticoechea9, Olga Maiz Alonso10, Raul Veroz11, Andrea García Valle12, Sergio Rodriguez Montero13, Roberto Miguelez14, Vega Jovani15, Marisa Hernandez Garfella16, Arantxa Conesa17, Olga Martinez Gonzalez18, Paula Rubio Muñoz19, Eva Peña Sainz-Pardo20, Miguel Ángel González-Gay21 and Ricardo Blanco2, 1Hospital Sierrallana, Torrelavega, Spain, 2Hospital Universitario Marques de Valdecilla, Santander, Spain, 3Hospital Universitario Marques de Valdecilla, Bezana, Spain, 4Hospital Basurto, Bilbao, Spain, 5Hospital del Tajo, Madrid, Spain, 6H. Lucus Augusti, Lugo, Spain, 7H. Mostoles, Madrid, Spain, 8H. Alava, Alava, Spain, 9Can Misses, Ibiza, Spain, 10Hospital Universitario Donostia, San Sebastian, Pais Vasco, Spain, 11H. Mérida, Mérida, Spain, 12H. Palencia, Palencia, Spain, 13H. Virgen de Valme, Sevilla, Spain, 14Toledo, Toledo, Spain, 15H. Alicante, Alicante, Spain, 16H. Valencia, Valencia, Spain, 17H. Castellón, Castellón, 18H. Salamanca, Salamanca, 19H. Esperit Sant, Barcelona, Spain, 20H. 12 de Octubre, Madrid, Spain, 21Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain

    Background/Purpose: Infliximab and adalimumab therapy has significantly improved the prognosis of patients with non-infectious refractory uveitis. However, there is not enough evidence for the use…
  • Abstract Number: 1379 • ACR Convergence 2020

    Clinical Outcomes Among Participants with Diffuse Systemic Sclerosis Contracting COVID-19 During Clinical Studies of Lenabasum: A Case Series

    Robyn Domsic1, Lorinda Chung2, Jerry Molitor3, Robert Spiera4, Bradley Bloom5, Barbara White6 and Quinn Dinh6, 1University of Pittsburgh School of Medicine, Pittsburgh, PA, 2Stanford University School of Medicine and Palo Alto VA Health Care System, Palo Alto, CA, 3University of Minnesota, Minneapolis, MN, 4Division of Rheumatology, Hospital for Special Surgery, New York, New York, USA, New York, NY, 5Corbus Pharmaceuticals Inc, Norwood, MA, 6Corbus Pharmaceuticals, Norwood, MA

    Background/Purpose: Patients with systemic sclerosis (SSc) may be at increased risk for severe outcomes with COVID-19, given the high rate of immunosuppressive medication use, underlying…
  • Abstract Number: 1478 • ACR Convergence 2020

    A Multidisciplinary Registry of Patients with Autoinmune and Immune-Mediated Diseases with Symptomatic COVID-19 Infection from a Single Center

    Juan C Sarmiento-Monroy1, Gerard Espinosa2, Fernanda Meira1, Berta Caballol3, Maria C Londoño3, Sara Llufriu3, Aina Moll1, Luis Fernando Quintana Porras1, Felipe Julio Ramirez Garcia4, José Inciarte-Mundo1, Elisabeth Solana1, Yolanda Blanco1, Eugenia Martinez1, Victor Llorens1, Sergio Prieto-González5, Georgina Espigol1, Jose C Milisenda1, Maria C. Cid5, Priscila Giavedoni1, Jose M Mascaró1, Isabel Blanco1, Joan Albert Barbera1, Oriol Sibila1, Jordi Gratacos-Gines1, Alfredo Adan2, Alvaro Agustí1, Raimon Sanmartí6, Julián Panés1, Ricard Cervera1, Jordi Vila1, Alex Soriano1, Jose Gómez-Puerta6 and On behalf INMUNOCOVID CLINIC7, 1Hospital Clinic de Barcelona, Barcelona, Catalonia, Spain, 2Hospital Clinic, Barcelona, Catalonia, Spain, 3Hospital Clinic de Barcelona, Barcelona, Spain, 4Arthritis Unit, Rheumatology Dpt, Hospital Clinic, Barcelona, Spain, Barcelona, Catalonia, Spain, 5Vasculitis Research Unit, Department of Systemic Autoimmune Diseases, Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain., Barcelona, Catalonia, Spain, 6Hospital Universitari Clínic de Barcelona, Barcelona, Catalonia, Spain, 7Hospital Clinic de Barcelona, Barcelona

    Background/Purpose: National health authorities reported a prevalence of SARS-CoV-2 infection around 7% of the general population in Barcelona county (1). A recent report focused on…
  • Abstract Number: 1802 • ACR Convergence 2020

    Vitamin D Level: Predictor of SLE Disease Activity in AA Cohort with CLE?

    Ileannette Robledo-Vega1, John Scheinuk2, Emmanuel Pardo2, Ansley Pratt2, Soham Mahato3, Andrew G. Chapple2 and Myriam Guevara4, 1Louisiana State University Health Sciences Center, New Orlenas, LA, 2Louisiana State University, New Orleans, LA, 3LSUHSC School of Public Health, New Orleans, LA, 4Lousiana State University Health Sciences Center, New Orleans, LA

    Background/Purpose: There are few predominant African American (AA) epidemiological studies in Cutaneous Lupus Erythematosus (CLE). The Gilliam classification divides CLE into lupus specific, acute cutaneous…
  • Abstract Number: PP06 • ACR Convergence 2020

    Only in My Dreams Can I Do the Things I Used to Do: Where There Is Research, There Is Hope

    Dan Smith1, Robert Smith1 and Jillian Covault1, 1Canton, MI

    Background/Purpose: In Mach 2020, I was diagnosed with relapsing polychondritis ("RP"), a multisystem, rheumatologic disease characterized by inflammation of cartilaginous structures including the ear, nose,…
  • Abstract Number: 0081 • ACR Convergence 2020

    Prevalence of Systemic Autoimmune Diseases in Polycystic Ovary Syndrome

    Saika Sharmeen1, Hafsa Nomani2, Erin Taub3 and Qingping Yao3, 1Stony Brook University Renaissance School of Medicine, Dix Hills, NY, 2Stony Brook University Renaissance School of Medicine, West Babylon, NY, 3Stony Brook University Renaissance School of Medicine, Stony Brook, NY

    Background/Purpose: Polycystic ovary syndrome (PCOS) is characterized by hormonal abnormality, chronic anovulation, hyperandrogenism, and obesity. Due to the hormonal imbalance, we hypothesize that patients with…
  • Abstract Number: 0430 • ACR Convergence 2020

    Outcomes of Coronavirus Disease 2019 Infection Among Patients Living with Rheumatic Diseases: A Matched Cohort Study from a US Multi-Center Research Network

    Kristin D'Silva1, April Jorge1, Na Lu2, Yuqing Zhang3, Zachary Wallace4 and Hyon Choi5, 1Massachusetts General Hospital, Boston, MA, 2Arthritis Research Canada, Vancouver, BC, Canada, 3Massachusetts General Hospital, Quincy, MA, 4Massachusetts General Hospital, Newton, MA, 5Massachusetts General Hospital, Department of Medicine, Division of Rheumatology, Lexington, MA

    Background/Purpose: Whether patients living with systemic autoimmune rheumatic diseases (SARDs) suffer from more severe complications of Coronavirus Disease 2019 (COVID-19) infection remains unknown.Methods: We conducted…
  • Abstract Number: 0607 • ACR Convergence 2020

    The Evolution of Rheumatologist’s Practice in Response to the COVID19 Pandemic

    Maria Bacalao1, Kathryn Dao2 and John Cush2, 1UT Southwestern, Dallas, TX, 2University of Texas Southwestern Medical School, Dallas, TX

    Background/Purpose: The COVID19 pandemic was a turning point for Rheumatology. This survey of rheumatologists (rheums) assessed its impact on care delivery, patient counseling and drug…
  • « Previous Page
  • 1
  • …
  • 61
  • 62
  • 63
  • 64
  • 65
  • …
  • 80
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology